Literature DB >> 22919879

Idiosyncratic adverse reactions of most frequent drug combinations longterm use among hospitalized patients with polypharmacy.

Edisa Trumic1, Nurka Pranjic, Lejla Begic, Fahir Becic, Mensura Asceric.   

Abstract

GOAL: Inappropriate prescribing of a multiple therapeutic agents to patients with chronic conditions is very common in everyday practice. Adverse drug reactions (ADRs) are still considered as one of the main problems of drug therapy. We investigated idiosyncratic symptoms and signs of adverse drug reactions (ADRs) of the most frequent used combination of drugs among hospitalized patients prescribed polypharmacy.
METHODOLOGY: A cross sectional study (design) was performed in Pharmacies "Eufarm Edal" in Tuzla from 2010 to 2011. Polypharmacy was defined as using > or =4 drugs. The total study sample of 166 examiners was interviewed with a questionnaire about ADRs which was developed special for study. Linear regression analyses was used to evaluate predictors of idiosyncratic signs of adverse drug reactions of the most prevalent drug combinations; using length of drugs in cases polypharmacy more than 6 months as independent variable. Age, sex, index of cumulative morbidity, drug number in polypharmacy, type of drug combination related pharmacological effects, type of hospital clinics were used as possible confounders.
RESULTS: The most common exposures to various drug combinations were: medication for high blood pressure and heart (62%), psychotropic drugs (59%), antacids (47%) and antibiotics (46%) among hospitalized patients with polypharmacy. Our results indicated that from 9.6% to 90.4% of hospitalized patients with polypharmacy had at least one suspicious long-term idiosyncratic drug combination use symptoms. The ADRs prevalence often used psychotropic drug combination was initiated suspected idiosyncratic adverse reactions: confusion, depression, anxiety, decreased libido and insomnia. Linear regression analyses also showed that it remains a very strange, and negative idiosyncratic and lacking therapeutic effects of use of antacids in conditions of polypharmacy.
CONCLUSION: The toxicity of some drug combinations may sometimes be synergistic and be greater than the sum of the risks of toxicity of either agent used alone. In order to recognize and to prevent ADRs (including drug interactions), good communication between pharmacist and patient and/or physicians and patient is crucial, and prescribers should develop an effective therapeutic partnership with the patient and with fellow health professionals.

Entities:  

Mesh:

Year:  2012        PMID: 22919879     DOI: 10.5455/medarh.2012.66.243-248

Source DB:  PubMed          Journal:  Med Arch        ISSN: 0350-199X


  5 in total

1.  Pattern of psychotropic prescription in a tertiary care center: a critical analysis.

Authors:  Pinaki Sarkar; Kaustav Chakraborty; Ajaya Misra; Rajnikant Shukla; Sarada Prasanna Swain
Journal:  Indian J Pharmacol       Date:  2013 May-Jun       Impact factor: 1.200

2.  A cross-sectional comparative study on the assessment of quality of life in psychiatric patients under remission treated with monotherapy and polypharmacy.

Authors:  Benson Koshy; C M Gopal Das; Yogananda Rajashekarachar; D R Bharathi; Shashank S Hosur
Journal:  Indian J Psychiatry       Date:  2017 Jul-Sep       Impact factor: 1.759

3.  Recycling antibiotics into GUMBOS: a new combination strategy to combat multi-drug-resistant bacteria.

Authors:  Marsha R Cole; Jeffery A Hobden; Isiah M Warner
Journal:  Molecules       Date:  2015-04-10       Impact factor: 4.411

4.  Drug-related problems among patients with infectious disease admitted to medical wards of Wollega University Referral Hospital: Prospective observational study.

Authors:  Firomsa Bekele; Ginenus Fekadu; Kumera Bekele; Dinka Dugassa; Jiregna Sori
Journal:  SAGE Open Med       Date:  2021-01-22

Review 5.  What is polypharmacy? A systematic review of definitions.

Authors:  Nashwa Masnoon; Sepehr Shakib; Lisa Kalisch-Ellett; Gillian E Caughey
Journal:  BMC Geriatr       Date:  2017-10-10       Impact factor: 4.070

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.